Press coverage about Gemphire Therapeutics (NASDAQ:GEMP) has been trending somewhat positive recently, according to Accern. The research firm identifies negative and positive press coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Gemphire Therapeutics earned a media sentiment score of 0.17 on Accern’s scale. Accern also assigned news articles about the company an impact score of 45.6091622853772 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
A number of analysts have commented on the company. Roth Capital restated a “buy” rating and issued a $30.00 price target on shares of Gemphire Therapeutics in a research note on Friday, December 22nd. Zacks Investment Research downgraded Gemphire Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, November 17th. HC Wainwright reiterated a “buy” rating and set a $22.00 target price (up from $21.00) on shares of Gemphire Therapeutics in a research report on Tuesday, November 14th. Piper Jaffray Companies reiterated an “overweight” rating and set a $22.00 target price on shares of Gemphire Therapeutics in a research report on Friday, October 27th. Finally, Canaccord Genuity reiterated a “buy” rating and set a $31.00 target price on shares of Gemphire Therapeutics in a research report on Monday, October 23rd. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average price target of $22.17.
Shares of Gemphire Therapeutics (NASDAQ:GEMP) opened at $7.52 on Friday. Gemphire Therapeutics has a twelve month low of $7.00 and a twelve month high of $21.59. The company has a debt-to-equity ratio of 1.00, a current ratio of 4.17 and a quick ratio of 4.17. The stock has a market capitalization of $79.11, a PE ratio of -2.22 and a beta of 3.07.
Gemphire Therapeutics (NASDAQ:GEMP) last issued its quarterly earnings data on Monday, November 13th. The company reported ($0.82) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.68) by ($0.14). research analysts anticipate that Gemphire Therapeutics will post -3.31 EPS for the current fiscal year.
About Gemphire Therapeutics
Gemphire Therapeutics Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the development and commercialization of therapeutics to treat cardiovascular and metabolic diseases. It is developing its product candidate, gemcabene (CI-1027), which is a once-daily, oral therapy for patients who are unable to achieve normal levels of low-density lipoprotein cholesterol (LDL-C) or triglycerides with approved therapies, primarily statin therapy.
Receive News & Ratings for Gemphire Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gemphire Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.